FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Clinical and Legal Considerations in Pharmaceutical Compounding JCAD The Journal of Clinical and Aesthetic Dermatology FDA takes first step in possible reversal of ban on some peptides The Washington Post BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 ( compounding only, no legal prescribing) into Category 1. This means